Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma

Bortezomib is the first proteasome inhibitor to treat a variety of malignancies and is currently part of the standard of care regimen for the initial treatment of patients with newly diagnosed multiple myeloma. While bortezomib is generally well tolerated, it has been associated with various side ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Joseph, Owji, Shayan, Agarwal, Aneesh, Kamat, Samir, Luu, Yen, Mubasher, Adnan, Niedt, George, Ray, Chloe, Cho, Hearn Jay, Gulati, Nicholas, Lamb, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366922/
https://www.ncbi.nlm.nih.gov/pubmed/37489455
http://dx.doi.org/10.3390/dermatopathology10030031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366922/
https://www.ncbi.nlm.nih.gov/pubmed/37489455
http://dx.doi.org/10.3390/dermatopathology10030031

Ejemplares similares